Beck Mack & Oliver’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Beck Mack & Oliver’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-122	Closed	-$36K	–	251
2016 Q2	$36K	Sell	122 -9	-7%	-$3.16K	﹤0.01%	271
2016 Q1	$56K	Hold	131	–	–	﹤0.01%	268
2015 Q4	$65K	Buy	+131	New	+$94.6K	﹤0.01%	278
2014 Q4	–	Sell	-121	Closed	-$163K	–	383
2014 Q3	$163K	Sell	121 -2	-2%	-$2.87K	﹤0.01%	343
2014 Q2	$208K	Hold	123	–	–	﹤0.01%	346
2014 Q1	$277K	Buy	123 +2	+2%	+$5.12K	0.01%	286
2013 Q4	$249K	Buy	121 +34	+39%	+$73.4K	0.01%	317
2013 Q3	$265K	Buy	+87	New	+$149K	0.01%	294

Other funds holding VYNT

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

FCM

Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

Beck Mack & Oliver's VYNT Position: Q3 2016 in Review

Beck Mack & Oliver sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2016, closing a stake of 122 shares — an estimated $36K sold.

Beck Mack & Oliver first reported a position in VYNT in Q3 2013 and held it in 8 quarters. The position peaked at $277K in Q1 2014. 30 funds tracked by Wall St. Rank hold VYNT as of Q3 2016.

Beck Mack & Oliver reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Beck Mack & Oliver sold 122 Vyant Bio, Inc. Common Stock shares in Q3 2016, an estimated $36K.
Beck Mack & Oliver first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 8 quarters.
Beck Mack & Oliver's Vyant Bio, Inc. Common Stock position peaked at $277K in Q1 2014.
30 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2016.

Based on Beck Mack & Oliver's 13F filing for Q3 2016, filed 28 Oct 2016.